{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:41:52Z","timestamp":1790811712805,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1010,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1038\/mtm.2014.33","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T14:37:51Z","timestamp":1407854271000},"page":"14033","source":"Crossref","is-referenced-by-count":129,"special_numbering":"C","title":["B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study"],"prefix":"10.1016","volume":"1","author":[{"given":"M","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ME","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DJ","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BK","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TJ","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Erger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Lavassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MM","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PA","family":"Doerfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RW","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BJ","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtm.2014.33_bib1","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2014.33_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben","year":"2002","journal-title":"Curr Mol Med"},{"key":"10.1038\/mtm.2014.33_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6neo\/6neo Pompe disease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"R1","key":"10.1038\/mtm.2014.33_bib4","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","article-title":"Pompe disease gene therapy","volume":"20","author":"Byrne","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mtm.2014.33_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mtm.2014.33_bib6","doi-asserted-by":"crossref","first-page":"12164","DOI":"10.1073\/pnas.210394597","article-title":"SBE-TAGS: an array-based method for efficient single-nucleotide polymorphism genotyping","volume":"97","author":"Hirschhorn","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2014.33_bib7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"key":"10.1038\/mtm.2014.33_bib8","first-page":"82","article-title":"Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy","volume":"106","author":"van der Beek","year":"2006","journal-title":"Acta Neurol Belg"},{"key":"10.1038\/mtm.2014.33_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/00007611-199305000-00015","article-title":"Respiratory insufficiency in adult-type acid maltase deficiency","volume":"86","author":"Moufarrej","year":"1993","journal-title":"South Med J"},{"key":"10.1038\/mtm.2014.33_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1096-8628(19960503)63:1<98::AID-AJMG19>3.0.CO;2-P","article-title":"Progress in medical genetics: map-based gene discovery and the molecular pathology of skeletal dysplasias","volume":"63","author":"McKusick","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.1038\/mtm.2014.33_bib11","series-title":"GeneReviews","author":"Leslie","year":"1993"},{"key":"10.1038\/mtm.2014.33_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mus.21933","article-title":"Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid a-glucosidase activity","volume":"43","author":"Bali","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1038\/mtm.2014.33_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr"},{"key":"10.1038\/mtm.2014.33_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mtm.2014.33_bib15","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1038\/mtm.2014.33_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mtm.2014.33_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMc0903652","article-title":"Vision 1 year after gene therapy for Leber's congenital amaurosis","volume":"361","author":"Cideciyan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2014.33_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1038\/mtm.2014.33_bib19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood"},{"key":"10.1038\/mtm.2014.33_bib20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2014.33_bib21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I\/II Trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib23","first-page":"298","article-title":"Tooth bleaching induces changes in the vascular permeability of rat incisor pulps","volume":"26","author":"Ferreira","year":"2013","journal-title":"Am J Dent"},{"key":"10.1038\/mtm.2014.33_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","article-title":"A largely random AAV integration profile after LPLD gene therapy","volume":"19","author":"Kaeppel","year":"2013","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2014.33_bib25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/hum.2006.17.1177","article-title":"Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults","volume":"17","author":"Brantly","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1038\/mtm.2014.33_bib27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/01.wnl.0000306309.85301.e2","article-title":"Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D","volume":"71","author":"Rodino-Klapac","year":"2008","journal-title":"Neurology"},{"key":"10.1038\/mtm.2014.33_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front Immunol"},{"key":"10.1038\/mtm.2014.33_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtm.2014.33_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2516.2008.01865.x","article-title":"Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor","volume":"15","author":"Aleem","year":"2009","journal-title":"Haemophilia"},{"key":"10.1038\/mtm.2014.33_bib31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1538-7836.2009.03332.x","article-title":"Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1038\/mtm.2014.33_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0037-1617028","article-title":"Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports","volume":"29","author":"Streif","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1038\/mtm.2014.33_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib34","first-page":"379","article-title":"Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions","volume":"15","author":"Masat","year":"2013","journal-title":"Discov Med"},{"key":"10.1038\/mtm.2014.33_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1038\/mtm.2014.33_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hep.25579","article-title":"Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients","volume":"57","author":"Levitsky","year":"2013","journal-title":"Hepatology"},{"key":"10.1038\/mtm.2014.33_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","article-title":"Mapping the T helper cell response to acid a-glucosidase in Pompe mice","volume":"106","author":"Nayak","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mtm.2014.33_bib38","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1538-7836.2009.03548.x","article-title":"Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells","volume":"7","author":"Nayak","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1038\/mtm.2014.33_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1038\/mtm.2014.33_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2014.33_bib42","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/mt.2011.81","article-title":"Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates","volume":"19","author":"Li","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2014.33_bib43","first-page":"e1","article-title":"Prevention of anti-capsid response following systemic AAV9 dosing infant rhesus monkeys","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2014.33_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2014.33_bib45","doi-asserted-by":"crossref","first-page":"e34684","DOI":"10.1371\/journal.pone.0034684","article-title":"Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors","volume":"7","author":"Karman","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/mtm.2014.33_bib46","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1038\/mtm.2014.33_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-0556-6-14","article-title":"Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet Vaccines Ther"},{"key":"10.1038\/mtm.2014.33_bib48","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2014.33_bib49","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2014.33_bib50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2014.33_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PEP.0b013e318288d370","article-title":"GMFM in infancy: age-specific limitations and adaptations","volume":"25","author":"Hielkema","year":"2013","journal-title":"Pediatr Phys Ther"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:50:30Z","timestamp":1565729430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050116301000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":51,"alternative-id":["S2329050116301000"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2014.33","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]},"article-number":"14033"}}